The new neuroprotective agent; BN83026 reduces L-DOPA-induced dyskinesia in hemiparkinsonian rats

被引：0
|
作者：
Spinnewyn, B.
Charnet, C.
Cornet, S.
Auguet, M.
Chabrier, P. E.
机构：
来源：
MOVEMENT DISORDERS | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
201
引用
收藏
页码：S153 / S154
页数：2
相关论文
共 50 条
  • [1] BN82451 and BN83026 reduce L-DOPA-induced dyskinesia in hemiparkinsonian rats
    Spinnewyn, B.
    Charnet, C.
    Cornet, S.
    Bernetiere, S.
    Camara, J.
    Auguet, M.
    Chabrier, P-E.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S140 - S140
  • [2] Nociceptive Response to l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats
    G. C. Nascimento
    K. Bariotto-dos-Santos
    C. R. A. Leite-Panissi
    E. A. Del-Bel
    M. Bortolanza
    Neurotoxicity Research, 2018, 34 : 799 - 807
  • [3] Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats
    Nascimento, G. C.
    Bariotto-dos-Santos, K.
    Leite-Panissi, C. R. A.
    Del-Bel, E. A.
    Bortolanza, M.
    NEUROTOXICITY RESEARCH, 2018, 34 (04) : 799 - 807
  • [4] Beneficial effects of the new multitargeting molecules BN82451 and BN83026 on tardive dyskinesia induced by haloperidol in rats
    Auguet, M.
    Charnet, C.
    Spinnewyn, B.
    Chabrier, R. -E.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S141 - S141
  • [5] New treatment (BN82451) and assessment for L-dopa-induced dyskinesias in hemiparkinsonian rats
    Spinnewyn, B.
    Rocher, M. N.
    Idrissi, M.
    Plas, P.
    Schmidlin, F.
    Ferrandis, E.
    Auguet, M.
    Chabrier, P. E.
    MOVEMENT DISORDERS, 2009, 24 : S71 - S71
  • [6] The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces L-DOPA-induced dyskinesia in hemiparkinsonian rats
    Cohen, Sophie R.
    Terry, Michelle L.
    Coyle, Michael
    Wheelis, Emily
    Centner, Ashley
    Smith, Samantha
    Glinski, John
    Lipari, Natalie
    Budrow, Carla
    Manfredsson, Fredric P.
    Bishop, Christopher
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2022, 217
  • [7] Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum
    Du, Huan
    Nie, Shuke
    Chen, Guiqin
    Ma, Kai
    Xu, Yan
    Zhang, Zhentao
    Papa, Stella M.
    Cao, Xuebing
    PARKINSONS DISEASE, 2015, 2015
  • [8] The Role of the Dorsal Raphe Nucleus in the Development, Expression, and Treatment of L-dopa-Induced Dyskinesia in Hemiparkinsonian Rats
    Eskow, Karen L.
    Dupre, Kristin B.
    Barnum, Christopher J.
    Dickinson, Sando O.
    Park, John Y.
    Bishop, Christopher
    SYNAPSE, 2009, 63 (07) : 610 - 620
  • [9] L-DOPA-induced dyskinesia
    Derkinderen, P
    Vidailhet, M
    REVUE NEUROLOGIQUE, 2002, 158 : S92 - S101
  • [10] Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats
    Barnum, Christopher J.
    Bhide, Nirmal
    Lindenbach, David
    Surrena, Margaret A.
    Goldenberg, Adam A.
    Tignor, Stefanie
    Klioueva, Anna
    Walters, Hannah
    Bishop, Christopher
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 100 (03) : 607 - 615
12345